https://www.selleckchem.com/products/az-33.html
gov was manually curated. Dual TAAs targeting BsAbs offer several advantages including increased tumor selectivity, potential to concurrently modulate two functional pathways in the tumor cell and may yield improved payload delivery. Dual TAAs targeting BsAbs represent a valuable class of biologics and early stage clinical studies have demonstrated promising anti-tumor efficacy in both hematologic malignancies and solid tumors. Dual TAAs targeting BsAbs represent a valuable class of biologics and early stage clinical studies have demonstr
Mi piace
Commento
Condividi
